Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04578756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04578756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2021
Completion date
October 6, 2025
Enrollment
310 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder (asd), bipolar i disorder, schizophrenia